A cartridge is configured to receive an injectable drug. The cartridge includes a body, and the body includes a proximal end portion having a proximal opening, a distal end portion having a distal opening, and a bore coupling the proximal opening and the distal opening. The cartridge further includes a pierceable septum coupled to the distal opening and a plunger movably carried within the bore. A volume is disposed in the bore between the pierceable septum and the plunger. The volume has a reduced pressure, and the reduced pressure is less than atmospheric pressure. A stopper is detachably coupled to the distal opening.
A61M 5/28 - Ampoules ou cartouches-seringues, c. à d. ampoules ou cartouches munies d'une aiguille
A61M 5/32 - Seringues - Parties constitutives - Parties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchon; Accessoires pour introduire l'aiguille dans le corps ou l'y maintenir; Dispositifs pour la protection des aiguilles
2.
GENE THERAPY FOR TREM2-ASSOCIATED DISEASES AND DISORDERS
Nucleic acids are described that encode for triggering receptor expressed on myeloid cells 2 (TREM2) and that can be used in expression constructs, vectors and gene therapies. Also described are methods of using the same for the treatment of TREM2-associated diseases and disorders, especially neurological diseases such as Alzheimer's Disease (AD), Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) or Nasu-Hakola Disease (NHD).
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
Methods for treating cancer patients with human platelet derived growth factor receptor alpha inhibiting compounds, in which the patient is identified as having a cancer that is human platelet derived growth factor receptor beta negative.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à quatre chaînons, p.ex. taxol
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p.ex. phloridzine liés à un système carbocyclique condensé, p.ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p.ex. cytidine, acide cytidylique
Described herein are variant adeno-associated virus (AAV) capsid polypeptides and gene therapeutics thereof for use in the treatment or prevention of hearing loss.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
The present invention generally relates to Fab-based antibody-like binding proteins comprising three antigen-binding domains that specifically bind one or more target proteins, wherein the antibody domain interfaces are engineered so that they readily self-assemble. The disclosure also provides methods for making trispecific binding proteins and uses of such binding proteins.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/32 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Product development; Pharmaceutical products development; Biological development services; Research and development services; Pharmaceutical drug development services; Scientific research and development; Scientific laboratory services, namely, providing shared wet laboratory facilities and shared laboratory apparatus and instruments for others; Analysis and evaluation of product development; Research and development of vaccines and medicines; Product research; Laboratory research; Biological research, clinical research and medical research; Research laboratory services; Scientific research consulting; Research and development in the field of biotechnology; Research and development in the pharmaceutical and biotechnology fields; Providing information relating to scientific research in the fields of biochemistry and biotechnology; Clinical trials; Research and development in the field of therapeutics. Providing medical support; Medical information; Medical testing; Medical analysis services.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
35 - Publicité; Affaires commerciales
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment, prevention and/or diagnosis of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease; Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment, prevention and/or diagnosis of dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, hearing loss, heart failure, inflammation and inflammatory diseases and disorders inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders; Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment, prevention and/or diagnosis of metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and vascular diseases; pharmaceutical preparations. Downloadable software for telehealth and telemedicine operations; downloadable computer software for prescribing, ordering, filling, managing, and providing information regarding prescription usage, dosage and directions; downloadable software for enabling patients to review details about medications and receive automated warnings of potential adverse interactions of medications; downloadable software for enabling patients to request, receive, track shipment of, and manage prescriptions and orders for pharmaceuticals; downloadable software for enabling patients to access general medical, health, and wellness information and advice. Pharmacy services; online retail pharmacy services; mail order pharmacy services; online retail store services featuring pharmaceuticals; online retail pharmacy services for the ordering, purchase, and delivery of pharmaceuticals; pharmaceutical services, namely, processing prescription orders. Platform as a service featuring computer software to permit users to identify, request and receive pharmacy products. Healthcare services; medical services; telemedicine services; arranging and providing medical information services relating to pharmaceuticals, namely, providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals.
23.
LASOFOXIFENE COMBINATION TREATMENT OF ER+ BREAST CANCER THAT HAS PROGRESSED ON A CDK4/6 INHIBITOR
Methods for reducing the progression of ER+breast cancer in a patient are provided, the methods comprising administering to the patient an effective amount of lasofoxifene or a pharmaceutically acceptable salt thereof and an effective amount of a CDK4/6 inhibitor (CDK4/6i), wherein the breast cancer: (i) is estrogen receptor positive (ER+); (ii) has at least one gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor 1 (ESR1) gene; and (iii) has progressed during prior CDK4/6 inhibitor therapy and/or has an oncogenic mutation in a gene other than ESR1.
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 31/506 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime non condensées et contenant d'autres hétérocycles
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
24.
METHODS AND SYSTEMS FOR USING CAUSAL NETWORKS TO DEVELOP MODELS FOR EVALUATING BIOLOGICAL PROCESSES
Aspects of the present disclosure relate to creating a graph, such as a directed-acyclic-graph (DAG), which represents the causal links in a biological process. In aspects, a researcher can establish the graph to incorporate the complexities of the biological process by specifying known or hypothetical causal relationships between nodes (e.g., parameters). Independence statements specifying which nodes should be independent of other nodes may then be derived, in some cases automatically, from the structure of the graph. Verification of each independence statement is performed based on experimental data. If all (or almost all) of the independence statements are verified, the researcher has a high degree of confidence in the DAG. If one or more independence statements cannot be experimentally verified, the DAG may need to be revised. These steps may be repeated to arrive at a robust DAG that is believed to accurately describe the biological process in the body.
G16B 25/10 - Profilage de l’expression de gènes ou de protéines; Estimation ou normalisation de ratio d’expression
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des micro-organismes viables
25.
WEARABLE SENSOR FOR MONITORING SOLID AND LIQUID CONSUMPTION
The present disclosure relates to a wearable device for monitoring food and drink intake of a wearer for creation of a consumption timeline of a wearer. The wearable device may make a distinction between food and drink consumption for greater reliability, which may increase effectiveness of patient care adjustment in relation to food-related afflictions. The wearable device may also be self-contained so that the user is not required to carry or keep track of a separate receiver for collection and processing of said consumption information.
The present invention provides improved reaction schemes and novel reaction intermediates for the synthesis of molecules useful as O-GlcNAcase (OGA) inhibitors.
C07D 213/61 - Atomes d'halogènes ou radicaux nitro
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. indolizine, bêta-carboline
27.
APPARATUSES FOR AND METHODS OF CONCENTRATING BIOMOLECULES
An apparatus is described for concentrating biomolecules in solution, such as oligonucleotide-containing solutions, via tangential flow filtration (TFF), where the apparatus can concentrate the oligonucleotides to a concentration > 100 mg/mL. Also described are methods of concentrating a biomolecule-containing solution, such as oligonucleotide-containing solutions, via TFF for high dose/low volume applications.
B01D 61/00 - Procédés de séparation utilisant des membranes semi-perméables, p.ex. dialyse, osmose ou ultrafiltration; Appareils, accessoires ou opérations auxiliaires, spécialement adaptés à cet effet
Nucleic acids are described that encode for triggering receptor expressed on myeloid cells 2 (TREM2) and that can be used in expression constructs, vectors and gene therapies. Also described are methods of using the same for the treatment of TREM2-associated diseases and disorders, especially neurological diseases such as Alzheimer's Disease (AD), Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) or Nasu-Hakola Disease (NHD).
C07K 14/005 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de virus
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C12N 7/00 - Virus, p.ex. bactériophages; Compositions les contenant; Leur préparation ou purification
C12N 15/00 - Techniques de mutation ou génie génétique; ADN ou ARN concernant le génie génétique, vecteurs, p.ex. plasmides, ou leur isolement, leur préparation ou leur purification; Utilisation d'hôtes pour ceux-ci
Provided herein are cocrystalline forms of FGFR3 inhibitors and gallic acid or nicotinamide coformers useful in the treatment and prevention of diseases which can be treated with a FGFR3 inhibitor, including FGFR3-associated diseases and disorders, characterizations and methods of making these cocrystalline forms.
The present invention generally relates to methods of reducing fatigue in a patient having ulcerative colitis with an anti-IL-23p19 antibody, in particular dosage regimens for the treatment of the disease.
C07K 16/24 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p.ex. antiacides, antisécrétoires, protecteurs de la muqueuse
Provided are crystalline forms of peptide fragments, method of preparation thereof, and use thereof for preparing peptides. The present crystalline compounds may be employed as intermediates with improved purity and physical properties for peptide syntheses.
C07K 5/103 - Tétrapeptides la chaîne latérale du premier amino-acide étant acyclique, p.ex. Gly, Ala
C07K 5/107 - Tétrapeptides la chaîne latérale du premier amino-acide contenant des carbocycles, p.ex. Phe, Tyr
C07K 5/113 - Tétrapeptides la chaîne latérale du premier amino-acide contenant plus de groupes carboxyle que de groupes amino, ou leurs dérivés, p.ex. Asp, Glu, Asn
C07K 5/117 - Tétrapeptides le premier amino-acide étant hétérocyclique, p.ex. Pro, His, Trp
C07K 7/00 - Peptides ayant de 5 à 20 amino-acides dans une séquence entièrement déterminée; Leurs dérivés
41 - Éducation, divertissements, activités sportives et culturelles
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Education services, namely, online and telephone coaching regarding the treatment of inflammatory bowel disease and autoimmune diseases and disorders Medical information services in the field of inflammatory bowel disease and autoimmune diseases and disorders
43.
COMPOSITIONS AND METHODS OF USE OF INTERLEUKIN-10 IN COMBINATION WITH IMMUNE CHECK-POINT PATHWAY INHIBITORS
The present disclosure provides a method for the treatment of neoplastic disease in a mammalian subject the method comprising the administration of an IL-10 agent in combination with the administration of at least one modulator of at least one immune checkpoint pathway. The present disclosure further provides a method for the treatment of neoplastic disease wherein the neoplasm has a low or intermediate tumor mutation burden, low or intermediate level of expression of the immune checkpoint molecule, or metastatic neoplastic disease.
The invention relates to an improvement in the field of injection-moulding technology. An improvement proposed includes a method for injection moulding of plastics parts (2), wherein, in order to produce a plastics part (2), liquefied plastics material is injected into a mould cavity (4), which is equipped with a core (5), of an injection mould (3). The method is characterized in that the core (5) is inductively heated before the plastics material is injected.
B29C 45/73 - Chauffage ou refroidissement du moule
B29C 45/04 - Appareils de moulage par injection avec moules mobiles
B29C 45/06 - Appareils de moulage par injection avec moules mobiles montés sur une table tournante
B29C 45/14 - Moulage par injection, c. à d. en forçant un volume déterminé de matière à mouler par une buse d'injection dans un moule fermé; Appareils à cet effet en incorporant des parties ou des couches préformées, p.ex. moulage par injection autour d'inserts ou sur des objets à recouvrir
Disclosed herein are dosing regimens for the administration of a compound of Formula I:
Disclosed herein are dosing regimens for the administration of a compound of Formula I:
or pharmaceutically acceptable salt thereof, or in combination with one or more of a second therapeutic agent, to a patient in need of such treatment.
The present disclosure provides human interleukin 4 receptor alpha antibody glucocorticoid receptor agonist conjugates and methods of using the conjugates for the treatment of inflammatory diseases, such as type 2 inflammatory diseases.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
A61K 47/55 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique l’agent de modification étant aussi un agent pharmacologiquement ou thérapeutiquement actif, c. à d. le conjugué entier étant un co-médicament, p.ex. un dimère, un oligomère ou un polymère de composés pharmacologiquement ou thérapeutiquement actifs
An embodiment of the invention relates to method for increasing HDL-C in a patient in need thereof. An embodiment of the invention relates to a method for decreasing high blood pressure. An embodiment relates to a treatment method for a patient with refractory type 2 diabetes to provide normal HbA1C glycemia.
The present invention provides a compound of Formula I: wherein R is H or; R133, R2is H, halogen, C1-C3 alkyl, C1-C3 alkoxy, or C2-C4 alkenyl; R3222222322222232222, C≡C, or a bond, wherein X is connected to phenyl ring A at the ortho or the meta position, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis and rheumatoid arthritis.
C07J 71/00 - Stéroïdes ayant le squelette du cyclopenta[a]hydrophénanthrène condensé avec un hétérocycle
A61P 5/44 - Glucocorticoïdes; Médicaments augmentant ou potentialisant l'activité des glucocorticoïdes
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrène; Leurs dérivés, p.ex. stéroïdes contenant des hétérocycles, p.ex. danazol, stanozolol, pancuronium ou digitogénine
57.
METHODS AND APPARATUS FOR INCREMENTAL LEARNING USING STORED FEATURES
Computerized techniques are provided for storing a set of representative features for use with a machine learning process. A first set of training images for a class are accessed and processed, using a feature extraction technique, to determine a set of features for the class. A set of representative features from the set of features for the class is determined using a selection technique. The set of representative features are stored for the class. A second set of images is accessed. The machine learning process is executed, using the stored set of representative features, including executing one or more of: a training phase to train a classifier using the second set of images and at least part of the stored set of representative features; and a testing phase to run the classifier using the second set of images and at least part of the stored set of representative features.
G06V 10/771 - Sélection de caractéristiques, p.ex. sélection des caractéristiques représentatives à partir d’un espace multidimensionnel de caractéristiques
G06V 10/77 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant l’intégration et la réduction de données, p.ex. analyse en composantes principales [PCA] ou analyse en composantes indépendantes [ ICA] ou cartes auto-organisatrices [SOM]; Séparation aveugle de source
G06V 10/776 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant l’intégration et la réduction de données, p.ex. analyse en composantes principales [PCA] ou analyse en composantes indépendantes [ ICA] ou cartes auto-organisatrices [SOM]; Séparation aveugle de source Évaluation des performances
The present disclosure relates to antibodies that bind human LAIR1 (“anti-human LAIR1 antibodies” or “anti-human LAIR1 antibodies”), compositions comprising such anti-human LAIR1 antibodies, and methods of using such anti-human LAIR1 antibodies.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61P 37/06 - Immunosuppresseurs, p.ex. médicaments pour le traitement du rejet de greffe
The present disclosure provides a drug delivery device. The drug delivery device is taken orally by a patient, and then activates within the gastrointestinal (GI) tract of the patient. Upon activation, arms of the drug delivery device expand, and penetrating tips penetrate the GI tract walls. A driver then drives a plunger within the drug delivery device, pushing a drug through the penetrating tips and through the GI tract walls of the patient. After a period of time, part of the drug delivery device dissolves and the drug delivery device passes through the GI tract.
A sensing system for determining a state of a compression spring is provided. The system may include capacitive plates positioned on opposite sides of the compression spring, a temperature sensor, and at least one processing circuit configured to measure a capacitance between the capacitive plates, measure a temperature based on a signal output by the temperature sensor, and determine whether the compression spring is in a compressed state or an expanded state based on the measured capacitance and the measured temperature. In some embodiments, the sensing system may be used to detect a state of a compression spring disposed on or within a medication-delivery device, so as to determine a state of the medication-delivery device. For example, the sensing system may be used to determine whether the medication-delivery device has been activated, or whether the device has completed delivery of the medication.
A61M 5/20 - Seringues automatiques, p.ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique
The present invention relates to a pharmaceutical composition comprising a dual incretin peptide that agonizes receptors for both human glucose dependent insulinotropic polypeptide (GIP) and glucagon like peptide 1 (GLP-1).
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p.ex. antidiabétiques
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p.ex. PEG, PPG, PEO ou polyglycérol
The present disclosure relates to antibodies that bind human LAIR1 ("anti-human LAIR1 antibodies" or "anti-human LAIR1 antibodies"), compositions comprising such anti-human LAIR1 antibodies, and methods of using such anti-human LAIR1 antibodies.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
64.
MEDICATION DELIVERY DEVICE INCLUDING DISPOSABLE AND REUSABLE PORTIONS
A medication delivery device includes a disposable portion and a reusable portion. The disposable portion includes a therapeutic agent delivery assembly, and the therapeutic agent delivery assembly includes a needle. The therapeutic agent delivery assembly is translatable from a stowed configuration to a deployed configuration. The reusable portion includes a first rack and pinion mechanism and a second rack and pinion mechanism. The first rack and pinion mechanism is actuatable to translate the therapeutic agent delivery assembly from the stowed configuration to the deployed configuration. The second rack and pinion mechanism is actuatable to translate a plunger and thereby cause the therapeutic agent delivery assembly to deliver a therapeutic agent from the needle.
A61M 5/315 - Pistons; Tiges de piston; Guidage, blocage, ou limitation des mouvements de la tige; Accessoires disposés sur la tige pour faciliter le dosage
A61M 5/28 - Ampoules ou cartouches-seringues, c. à d. ampoules ou cartouches munies d'une aiguille
The present invention provides a method for improving glycemic control in a patient in need thereof, comprising administering to said patient, tirzepatide, or a pharmaceutically acceptable salt thereof, wherein said patient has failed to reach their HbA1c goal using GLP-1 RA treatment. The present invention provides a method for improving weight management in a patient in need thereof, comprising administering to said patient tirzepatide, or a pharmaceutically acceptable salt thereof, wherein said patient has failed to reach their weight management goal using GLP-1 RA treatment.
Methods of modulating expression and / or secretion of at least one of IRG1, TNFα, IL-6, IL-1b, itaconate, CXCL-10, IRAK4, major histocompatibility complex II (MHC II), and NFκB in a subject and method of treating or preventing a disease or a condition in a subject via modulation thereof.
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
A61K 31/711 - Acides désoxyribonucléiques naturels, c. à d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
Described herein are fixed doses and dosing regimens for long-acting insulin receptor agonists suitable for once-weekly dosing, such as weekly basal insulin-Fc (BIF).
A61K 47/10 - Alcools; Phénols; Leurs sels, p.ex. glycérol; Polyéthylène glycols [PEG]; Poloxamères; Alkyléthers de PEG/POE
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol o
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p.ex. antidiabétiques
A medication delivery device including a device body and a dose setting component coupled to the device body. Component is rotatable relative to the device body in relation to an amount of a set or delivered dose. An annular sensed element, such as a metal or magnetic ring, is positioned on a proximal surface of the dose setting component. A carrier secures the sensed element to the dose setting component. The carrier includes a proximal overlapping support that is contactable against the sensed element opposite the proximal surface of the dose setting component. The carrier is configured to axially and rotationally fix the sensed element to the dose setting component. The device may include a dose detection system operable with the sensed element.
A61M 5/315 - Pistons; Tiges de piston; Guidage, blocage, ou limitation des mouvements de la tige; Accessoires disposés sur la tige pour faciliter le dosage
71.
HUMAN TUMOR NECROSIS FACTOR ALPHA ANTIBODY GLUCOCORTICOID CONJUGATES
The present disclosure provides human tumor necrosis factor alpha antibody glucocorticoid receptor agonist conjugates and methods of using the conjugates for the treatment of autoimmune and inflammatory diseases.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrène; Leurs dérivés, p.ex. stéroïdes contenant des hétérocycles, p.ex. danazol, stanozolol, pancuronium ou digitogénine
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p.ex. arthrites, arthroses
C07K 16/24 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
72.
PYRAZOLO[1,5-A]PYRIDINE AND IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS FGFR3 INHIBITORS FOR THE TREATMENT OF CANCER
The present invention provides compounds of the formula as fibroblast growth factor receptor 3 (FGFR3) inhibitors for the treatment of e.g. cancer, systemic sclerosis, fibrosis, pulmonary fibrosis, achondroplasia, thanatophoric dysplasia, severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), and muenke syndrome. Preferred compounds are e.g. pyrazolo[1,5-a]pyridine and imidazo[1,2-a]pyridine derivatives.
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. indolizine, bêta-carboline
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
A61P 19/00 - Médicaments pour le traitement des troubles du squelette
A61P 19/04 - Médicaments pour le traitement des troubles du squelette des troubles non-spécifiques du tissu conjonctif
73.
CO-CRYSTALS OF 4-[4-[3-CHLORO-4-[1-(2-PYRIDYL)-2-HYDROXY-ETHOXY]PYRAZOLO[1,5-A]PYRIDIN-6-YL]-5-METHYL- TRIAZOL-1-YL]PIPERIDINE-1 -CARBONITRILE DERIVATIVES WITH GALLIC ACID AND NICOTINE AMIDE
The present invention relates to cocrystalline forms of 4-[4-[3- chloro-4-[l-(5-fluoro-2-pyridyl)-2-hydroxy-ethoxy]pyrazolo[l,5- a]pyridin-6-yl]-5-methyl-triazol-l-yl]piperidine-l-carbonitrile, R- enantiomer ("Isomer 2"), with gallic acid (I), and to cocrystalline forms of 4-[4-[3-chloro-4-[l-(2-pyridyl)-2- hydroxy-ethoxy]pyrazolo[l,5-a]pyridin-6-yl]-5-methyl-triazol-l- yl]piperidine-l-carbonitrile, R-enantiomer ("Isomer A"), with gallic acid or nicotine amide (II) The compounds are fibroblast growth factor receptor 3 (FGFR3) inhibitors for use in methods of treatment of e.g. cancer. Provided herein are also methods for the preparation of said cocrystalline forms.
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. indolizine, bêta-carboline
Small molecule potentiatiors to potassium channels (such as Kv7 potentiators—which are also called KCNQ potentiators), compositions including such compounds, and methods of using such compounds for the treatment of Amyotrophic Lateral Sclerosis and other neurological diseases caused by changes in motor neuron excitability, including, but not limited to, primary lateral sclerosis, pseudobulbar palsy, progressive bulbar palsy, progressive muscular atrophy and epilepsy.
C07D 213/38 - Radicaux substitués par des atomes d'azote liés par des liaisons simples comportant uniquement de l'hydrogène, ou des radicaux hydrocarbonés, liés à l'atome d'azote substituant
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C07D 213/64 - Un atome d'oxygène lié en position 2 ou 6
Systems, methods, and devices are provided for predicting a status of an infusion site. Approaches include applying a regression model to physiological glucose data and insulin delivery data to generate predictive data, operating a trained machine learning model to process the predictive data to generate an output, and determining that the infusion site has failed or is likely to have failed based on the output.
G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p.ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p.ex. pour s’assurer de l’administration correcte aux patients
G16H 20/17 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p.ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p.ex. pour s’assurer de l’administration correcte aux patients administrés par perfusion ou injection
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
The present invention relates to a dosage form suitable for oral administration comprising a therapeutic peptide or protein in a sealed capsule having a co-polymer coating.
Drug-delivery systems configured to generate indications regarding a user's level of skill, familiarity, or experience with operating such systems are described. The systems may comprise a syringe assembly, one or more skin contact sensors, and one or more syringe assembly sensors configured to detect initiation and/or completion of a dispensing event. The system may further comprise one or more processing circuits configured to measure a time duration between when the skin contact sensor(s) detect contact with skin tissue and when the syringe assembly initiates a dispensing event, compare the measured duration against a threshold time duration, and generate a user indication signal if the measured duration exceeds the threshold time duration.
A61M 5/20 - Seringues automatiques, p.ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
16 - Papier, carton et produits en ces matières
25 - Vêtements; chaussures; chapellerie
36 - Services financiers, assurances et affaires immobilières
41 - Éducation, divertissements, activités sportives et culturelles
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Downloadable software in the nature of a mobile application for providing healthcare-related information, medication reminders, and tracking medication dosing history; the foregoing related to the management and treatment of diabetes, obesity, overweight, and metabolic diseases Medical apparatus and instruments for use in the diagnosis and treatment of diabetes, obesity, overweight, and metabolic diseases Printed materials, namely, notepads, pamphlets and brochures for patients and health professionals in the field of diabetes, obesity, overweight, and metabolic diseases Clothing, namely shirts and hats Financial assistance in connection with the purchase of pharmaceutical preparations in the field of diabetes, obesity, overweight, and metabolic diseases Education services, namely online and telephone coaching regarding the management and treatment of diabetes, obesity, overweight, and metabolic diseases Medical and scientific research in the field of diabetes, obesity, overweight, and metabolic diseases
The present invention relates to specific salts of (1S,5R)-(1α,5α,6α)-N-[1,1-dimethyl-2-[(3-methyl-2-pyridyl)oxy]ethyl]-3-azabicyclo[3.1.0]hexane-6-carboxamide, to pharmaceutical compositions comprising said salts, to methods of using said salts to treat physiological disorders, and to intermediates useful in the synthesis of the salts.
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
41 - Éducation, divertissements, activités sportives et culturelles
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Educational services on the topic of medical matters; arranging and conducting educational forums on medical matters. Research and development; Consulting services in the fields of research and development; Development of technology, consumer goods, software; Medical and pharmaceutical information services in all media in relation to the foregoing.
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Providing medical research data captured from wearable biosensors in the field of pharmaceuticals and clinical trials. Medical information services in the field of pharmaceuticals and clinical trials.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment, prevention and/or diagnosis of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease; Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment, prevention and/or diagnosis of dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, hearing loss, heart failure, inflammation and inflammatory diseases and disorders inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders; Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment, prevention and/or diagnosis of metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and vascular diseases; pharmaceutical preparations. Medical information services in the field of diabetes, endocrine diseases and disorders, metabolic diseases and disorders and obesity; medical information services.
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Providing medical research data captured from wearable biosensors in the field of pharmaceuticals and clinical trials. Medical information services in the field of pharmaceuticals and clinical trials.
Provided herein are novel N- and C-terminal oxyntomodulin polypeptide binding molecules, and uses thereof, including a method for quantitating oxyntomodulin.
C07K 16/26 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des hormones
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
G01N 33/74 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des hormones
88.
PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE
The embodiments of present invention provide processes and an intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide hemisuccinate, and formulations and product forms made by these processes. The embodiments of the present invention further provide for the preparation of lasmiditan acetate, 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide acetate salt, and/or pharmaceutical compositions thereof, and/or uses of lasmiditan acetate and formulations thereof in subcutaneous drug delivery.
C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
Provided herein are proteins comprising one monovalent human TfR binding domain (“human TfR binding proteins”), proteins comprising one monovalent mouse TfR binding domain (“mouse TfR binding proteins”), conjugates comprising such human or mouse TfR binding proteins, e.g., human TfR binding proteins-dsRNA conjugates, pharmaceutical compositions comprising human TfR binding proteins or conjugates, and methods of treating CNS diseases (e.g., neurodegenerative disease such as neurodegenerative synucleinopathy or tauopathy) using human TfR binding proteins or conjugates.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
90.
PD-1 AGONIST ANTIBODIES AND METHODS OF TREATING AUTOIMMUNE DISEASES WITH A PD-1 AGONIST ANTIBODY
The present disclosure relates to novel PD-1 agonist antibodies and methods and uses of anti-human PD-1 agonist antibodies for the treatment of autoinflammatory and/or autoimmune diseases. Also provided are doses and dosing regimens for the methods and uses of anti- human PD-1 agonist antibodies for the treatment of autoinflammatory and/or autoimmune diseases such as RA.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
Described herein are doses and dosing regimens comprising determining and administering doses of long-acting insulin receptor agonists suitable for once-weekly dosing, such as Weekly Basal Insulin-Fc (BIF).
Provided herein are proteins comprising one monovalent human TfR binding domain ("human TfR binding proteins"), proteins comprising one monovalent mouse TfR binding domain ("mouse TfR binding proteins"), conjugates comprising such human or mouse TfR binding proteins, e.g., human TfR binding proteins-dsRNA conjugates, pharmaceutical compositions comprising human TfR binding proteins or conjugates, and methods of treating CNS diseases (e.g., neurodegenerative disease such as neurodegenerative synucleinopathy or tauopathy) using human TfR binding proteins or conjugates.
The present invention provides compounds of the formula:
The present invention provides compounds of the formula:
wherein A, B, D1, X, Y, Z, G, R1, R2, and R3a are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer.
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
C07D 491/048 - Systèmes condensés en ortho avec un seul atome d'oxygène comme hétéro-atome du cycle contenant de l'oxygène le cycle contenant de l'oxygène étant à cinq chaînons
95.
Methods for Producing Fabs and IgG Bispecific Antibodies
The University of North Carolina at Chapel Hill (USA)
Inventeur(s)
Demarest, Stephen John
Froning, Karen Jean
Kuhlman, Brian Arthur
Leaver-Fay, Andrew Philip
Abrégé
Methods for producing Fabs and IgG bi-specific antibodies comprising expressing nucleic acids encoding designed residues in the CH1/CL interface are provided. Also provided are Fabs and IgG bi-specific antibodies produced according to the provided methods as well as nucleic acids, vectors and host cells encoding the same.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/32 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
Drug delivery devices are provided having a needle assembly portion and a drug device portion, where the needle assembly portion is removably coupleable to the drug device portion. In some embodiments, the needle of the needle assembly may be moveable between a retracted position and an extended position for piercing into a subjects skin.
A61M 5/28 - Ampoules ou cartouches-seringues, c. à d. ampoules ou cartouches munies d'une aiguille
A61M 5/32 - Seringues - Parties constitutives - Parties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchon; Accessoires pour introduire l'aiguille dans le corps ou l'y maintenir; Dispositifs pour la protection des aiguilles
A61M 5/34 - Structures pour le raccordement de l'aiguille
A61M 5/50 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaire; Accessoires à cet effet, p.ex. dispositifs de remplissage ou de nettoyage, appuis-bras avec des moyens pour empêcher la réutilisation ou pour indiquer si le dispositif est défectueux, usagé, non stérile ou si l'on a tenté de l'utiliser
A61M 5/20 - Seringues automatiques, p.ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Scientific research and development; Scientific laboratory services, namely, providing shared wet laboratory facilities and shared laboratory apparatus and instruments for others; Laboratory research; Biological research, clinical research and medical research; Research laboratory services; Scientific research consulting; Providing information relating to scientific research in the fields of biochemistry and biotechnology; Research and development in the field of therapeutics. Providing medical support; Medical information; Medical testing; Medical analysis services.
